Evidence map›Paper›PMID 21264255›Full record

ArticlePloS one2011

The antiviral spectra of TRIM5α orthologues and human TRIM family proteins against lentiviral production.

Seiga Ohmine, Ryuta Sakuma, Toshie Sakuma, Tayaramma Thatava, Hiroaki Takeuchi, Yasuhiro Ikeda

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of Human TRIM5α in Intrinsic Immunity.Frontiers in microbiology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Seiga OhmineDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Ryuta Sakuma
Toshie Sakuma
Tayaramma Thatava
Hiroaki Takeuchi
Yasuhiro Ikeda
Mayo Clinic · USNational Institute of Infectious Diseases · JPWinnMed · US

Funding

TRIM5alpha-mediated block of HIV-1 productionR56AI074363 · NIAID · MAYO CLINIC ROCHESTER · PI IKEDA, YASUHIRO · 2008 to 2008
$340k
NIAID NIH HHS 1R56AI074363-01A1NIAID NIH HHS R56 AI074363
6 · The paper itself

Abstract

backgroundRhesus monkey TRIM5α (TRIM5αrh) recognizes the incoming HIV-1 core through its C-terminal B30.2(PRYSPRY) domain and promotes its premature disassembly or degradation before reverse transcription. Previously, we have shown that TRIM5αrh blocks HIV-1 production through the N-terminal RBCC domain by the recognition of Gag polyproteins. Although all TRIM family proteins have RBCC domains, it remains elusive whether they possess similar late-restriction activities. METHODOLOGY/PRINCIPAL

findingsWe examined the antiviral spectra of TRIM5α orthologues and human TRIM family members which have a genetic locus proximal to human TRIM5α (TRIM5αhu), against primate lentiviral production. When HIV-1 virus-like particles (VLPs) were generated in the presence of TRIM5α proteins, rhesus, African green and cynomolgus monkey TRIM5α (TRIM5αag and TRIM5αcy), but not TRIM5αhu, were efficiently incorporated into VLPs, suggesting an interaction between HIV-1 Gag and TRIM5α proteins. TRIM5αrh potently restricted the viral production of HIV-1 groups M and O and HIV-2, but not simian lentiviruses including SIV(MAC)1A11, SIV(AGM)Tan-1 or SIV(AGM)SAB-1. TRIM5αhu did not show notable late restriction activities against these lentiviruses. TRIM5αag and TRIM5αcy showed intermediate restriction phenotypes against HIV-1 and HIV-2, but showed no restriction activity against SIV production. A series of chimeric TRIM5α constructs indicated that the N-terminal region of TRIM5αag and TRIM5αcy are essential for the late restriction activity, while the C-terminal region of TRIM5αcy negatively regulates the late restriction activity against HIV-1. When select human TRIM family proteins were examined, TRIM21 and 22 were efficiently incorporated into HIV-1 VLPs, while only TRIM22 reduced HIV-1 titers up to 5-fold. The antiviral activities and encapsidation efficiencies did not correlate with their relative expression levels in the producer cells. CONCLUSIONS/SIGNIFICANCE: Our results demonstrated the variations in the late restriction activities among closely related TRIM5α orthologues and a subset of human TRIM family proteins, providing further insights into the late restriction activities of TRIM proteins.

Indexed as

AnimalsAntiviral AgentsAntiviral Restriction FactorsBinding SitesCarrier Proteinsgag Gene Products, Human Immunodeficiency VirusHaplorhiniHIV-1HumansLentivirusTripartite Motif ProteinsUbiquitin-Protein LigasesViral ProteinsVirionAntiviral AgentsAntiviral Restriction FactorsCarrier Proteinsgag Gene Products, Human Immunodeficiency VirusTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesViral Proteins

Identifiers

PMID21264255
PMCPMC3021539
OpenAlexW2086206247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.